`
`Page 1 of 1
`
`For US journalists only. For non-US journalists, please click here.
`
`®
`Novartis gains FDA approval for Afinitor
`in advanced breast cancer marking a
`significant milestone for women battling
`this disease
`
`
`
`• Approval represents the first major advance for US
`patients with advanced HR+ breast cancer since aromatase
`1
`inhibitors were introduced more than 15 years ago
`
`• In a Phase III trial, Afinitor plus exemestane more than
`doubled the time women lived before the cancer worsened
`2
`compared to exemestane alone
`
`• Afinitor, the first mTOR inhibitor approved for advanced
`HR+ breast cancer, is given after the disease progresses
`2
`following prior therapy with letrozole or anastrozole
`
`East Hanover, N.J., July 20, 2012 – The US Food and
`®
`Drug Administration (FDA) has approved Afinitor
`(everolimus) tablets for the treatment of postmenopausal
`women with advanced hormone receptor-positive, HER2-
`
`
`
`
`
`Media Contacts
`
`Additional Resources
`
`Broadcast Quality Video
`
`Julie Masow
`Novartis Corporation
`+1 212 830 2465 (direct)
`+1 862 579 8456 (mobile)
`julie.masow@novartis.com
`
`Gloria Vanderham
`Novartis Oncology
`+1 862 778 4268 (direct)
`+1 862 926 8420 (mobile)
`gloria.vanderham@novartis.com
`
`Novartis Newsmarket
`Novartis Oncology
`Novartis
`
`Download Afinitor B-roll Footage
`
`http://www.multivu.com/players/English/56006-novartis-afinitor-fda-approval/
`
`1/28/2016
`
`NPC02233748
`
`NOVARTIS EXHIBIT 2153
`Par v Novartis, IPR 2016-00084
`Page 1 of 1